IONIS CEO acquires 484 shares via ESPP

IONIS PHARMACEUTICALS INC CEO Brett P. Monia acquired 484 shares of common stock on February 27, 2026 through the company’s Amended and Restated 2000 Employee Stock Purchase Plan at $48.8665 per share.

Rhea-AI Filing Summary

IONIS PHARMACEUTICALS INC CEO Brett P. Monia acquired 484 shares of common stock on February 27, 2026 through the company’s Amended and Restated 2000 Employee Stock Purchase Plan at $48.8665 per share. After this transaction, the CEO directly owns 254,981 shares. These shares may not be sold until August 27, 2026.

Insider Trade Summary

Other: 484 shares

Other 1 txn

Insider Monia Brett P

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Other	Common Stock	484	$48.8665	$24K

Holdings After Transaction: Common Stock — 254,981 shares (Direct)

Footnotes (1)

1. F1. Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 27, 2026. These shares may not be sold until August 27, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IONIS (IONS) report for Brett P. Monia?

IONIS reported that CEO Brett P. Monia acquired 484 common shares on February 27, 2026 through the company’s employee stock purchase plan. The shares were bought at $48.8665 per share and increase his direct ownership stake in the company.

At what price did the IONIS (IONS) CEO acquire shares in this Form 4?

The CEO acquired 484 IONIS shares at $48.8665 per share through the employee stock purchase plan. This plan-based purchase reflects a fixed transaction price and adds to his existing holdings reported in the Form 4 filing.

How many IONIS (IONS) shares does CEO Brett P. Monia hold after this transaction?

After the reported transaction, CEO Brett P. Monia directly holds 254,981 IONIS common shares. This figure includes the 484 shares acquired under the employee stock purchase plan and represents his direct ownership following the February 27, 2026 transaction.

When can the newly acquired IONIS (IONS) shares be sold by the CEO?

The 484 shares acquired under the IONIS employee stock purchase plan on February 27, 2026 may not be sold until August 27, 2026. This holding restriction is specified in the footnotes to the insider transaction disclosure.

What plan was used for the IONIS (IONS) CEO’s February 27, 2026 share purchase?

The CEO’s 484-share purchase was made under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan. This plan allows eligible employees, including executives, to buy company stock on specified terms outlined in the program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 05:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Monia Brett P

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CA 92010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		J		484(1)	A	$48.8665	254,981	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 27, 2026. These shares may not be sold until August 27, 2026.

	By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.